
==== Front
Eur Respir Rev
Eur Respir Rev
ERR
errev
European Respiratory Review
0905-9180
1600-0617
European Respiratory Society

10.1183/16000617.0005-2024
ERR-0005-2024
Version of Record
Reviews
9
Respiratory management of acute chest syndrome in children with sickle cell disease
Respiratory management of acute chest syndrome in children with SCD
https://orcid.org/0000-0001-6353-3136
Ahmed Bushra 1
https://orcid.org/0000-0002-5366-4594
Arigliani Michele 1
https://orcid.org/0000-0002-1610-0335
Gupta Atul 23
1 UCL GOS Institute of Child Health, University College London, London, UK
2 King's College Hospital, King's College London, London, UK
3 Faculty of Life Sciences and Medicine, King's College London, London, UK
Corresponding author: Atul Gupta (atul.gupta@kcl.ac.uk)
7 2024
18 9 2024
33 173 24000508 1 2024
01 7 2024
Copyright ©The authors 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Acute chest syndrome (ACS) is a leading cause of respiratory distress and hospitalisation in children with sickle cell disease (SCD). The aetiology is multifactorial and includes fat embolism, venous thromboembolism, alveolar hypoventilation and respiratory infections, with the latter being particularly common in children. These triggers contribute to a vicious cycle of erythrocyte sickling, adhesion to the endothelium, haemolysis, vaso-occlusion and ventilation–perfusion mismatch in the lungs, resulting in the clinical manifestations of ACS. The clinical presentation includes fever, chest pain, dyspnoea, cough, wheeze and hypoxia, accompanied by a new pulmonary infiltrate on chest radiography. Respiratory symptoms may overlap with those of acute asthma, which may be difficult to distinguish. Patients with ACS may deteriorate rapidly; thus prevention, early recognition and aggressive, multidisciplinary team management is essential. In this narrative review, we highlight the current evidence regarding the epidemiology, pathophysiology, treatment and preventative strategies for ACS, focusing on the aspects of major interest for the paediatric pulmonologist and multidisciplinary team who manage children with SCD.

Shareable abstract

Acute chest syndrome is a common and potentially life-threatening complication of sickle cell disease. This review summarises current evidence on the respiratory management of acute chest syndrome in children with sickle cell disease. https://bit.ly/3LeDSip
==== Body
pmcIntroduction

Sickle cell disease (SCD) is the most common inherited haemoglobinopathy worldwide and is estimated to affect over 300 000 neonates [1] every year. Pulmonary complications have a great impact on the morbidity and survival of people with SCD [2] and acute chest syndrome (ACS) is the most common acute manifestation. Although the disease course is generally milder in children than in adults [3], the incidence of ACS episodes is highest in childhood [4–8] and recurrent ACS episodes may be associated with greater chronic lung function impairment [9, 10].

In this narrative review, we aim to provide an overview of the epidemiology, pathophysiology, clinical presentation and respiratory management of ACS in children. We have focused on the aspects of major interest for the paediatric pulmonologist and the paediatric multidisciplinary team. Other aspects of ACS management in children that do not involve the lung are not covered in detail here as extensive haematology literature on the topic is available.

A literature search was carried out in PubMed to identify relevant studies using the MeSH headings “acute chest syndrome” and “sickle cell” with the following filters applied: children aged birth to 18 years and English language only. Abstracts were screened for applicability. However, as this is not a systematic review, we cannot dismiss that some relevant studies may have been omitted.

Epidemiology

In the pre-hydroxyurea era, the prospective Cooperative Study of Sickle Cell Disease (CSSCD) showed that the incidence of ACS peaked between the age of 2 and 4 years at 25 events per 100 patient-years, with approximately half of haemoglobin (Hb) sickle cell (HbSS) having suffered at least one ACS episode by the age of 5 years. [5] Children younger than 4 years of age at the time of the first ACS event have an increased risk of future episodes [6, 8, 11], recurrent ACS episodes [12] and rehospitalisation within 1 year [8]. The fall in fetal Hb levels after infancy and the high incidence of viral respiratory infections at preschool age are likely to be the key factor contributing to the high rates of ACS between 2 and 5 years of age.

The occurrence of any episodes of ACS before 20 years of age is associated with increased mortality [4] and a recent episode of ACS in the preceding 2 weeks is associated with increased risk of subsequent ischaemic cerebrovascular accident [13].

Initiating hydroxyurea early and implementing pneumococcal vaccination have shifted ACS epidemiology. In the Baby Hug trial, children aged 9–18 months with HbSS and HbS-beta0- thalassemia, who received hydroxyurea for 2 years, had an incidence of ACS of 4.2 per 100 patient-years versus 14.6 per 100 patient-years in the placebo group (hazard ratio 0.36; p=0.02). More recently, Assad et al. [14] showed that, in France, the implementation of prevenar-13 (pneumococcal vaccination) led to a 40% reduction in incidence of ACS among children with SCD.

Patients with HbSS and HbS-beta0-thalassemia face the highest risk for ACS, with higher fetal Hb levels reducing odds [15]. Currently, no reliable biomarkers exist for ACS risk stratification in SCD patients [16].

Aetiology and risk factors

The multifactorial aetiology of ACS includes factors such as pulmonary infections, fat embolism, venous thromboembolism, alveolar hypoventilation and dysregulation of the arginine–nitric oxide (NO) pathway. These triggers lead to a vicious cycle of erythrocyte sickling, adhesion to the endothelium, haemolysis, vaso-occlusion and ventilation–perfusion (Vʹ/Qʹ) mismatch, resulting in the clinical manifestations of ACS.

In adults, most cases occur following a vaso-occlusive crisis (VOC), which also happens in approximately half of the ACS episodes in children [3, 17].

Respiratory infections

Lower respiratory tract infections triggering ACS are particularly relevant in children. The incidence of ACS in children is three-fold higher in the winter than in the summer [3], likely due to the increased circulation of respiratory viruses, such as respiratory syncytial virus (RSV), which has been frequently isolated during ACS episodes [17]. In addition, influenza viruses may trigger ACS episodes, with H1N1 influenza A virus being associated with higher odds [18]. ACS has been also reported in association with coronavirus disease 2019 in children [19, 20]; a large international registry showed that, among 360 subjects with SCD younger than 18 years who tested positive for severe acute respiratory syndrome coronavirus 2 between March 2020 and March 2021, 14.8% (24 out 360) developed ACS [21]. However, an observational study of 101 preschool children presenting with fever and/or ACS found that although rhinovirus, adenovirus, RSV and parainfluenza were frequently detected on multiplex PCR, their rates did not differ significantly between those who developed ACS and those who did not [22]. Thus, whilst the detection of respiratory viruses is common, they do not fully explain the high incidence of ACS episodes in preschool children.

People with SCD are at higher risk of infections by encapsulated bacteria, such as Streptococcus pneumoniae, due to autospelectomy [23] and/or surgical splenectomy. In the National Acute Chest Syndrome Study (NACSS), in which sputum or bronchoalveolar lavage (BAL) with nasopharyngeal aspirate and serology was prospectively analysed in 672 ACS episodes of 538 children and adults in the USA between 1993 and 1997, Streptococcus pneumoniae was found in only 4.5% of cases [17]. Recent evidence, however, showing a remarkable decrease in the incidence of ACS in children following prevenar-13 implementation [14], suggests that the burden of pneumococcus in ACS is probably higher than previously thought.

Atypical pathogens Mycoplasma pneumoniae and Chlamydia pneumoniae can also contribute to the pathogenesis of ACS. The NACSS cohort [17] showed microbiological or serological evidence of acute infection with these two bacteria in 29% and 19% of children with ACS below 10 years of age, respectively. In contrast, Chlamydia pneumoniae was more frequent in adolescents [24].

Fat embolism

Fat embolism can occur during VOC, with lipid-laden macrophages often detected in the BAL of adult patients with ACS [25–27]. Vichinsky et al. [28] reported lipid-laden macrophages in the BAL of 12 out of 27 children (44%) with ACS. These subjects presented with pain and were more likely to have multi-segmental involvement and severe clinical presentation than their peers without pulmonary fat embolism [28]. However, it is important to highlight that lipid-laden macrophages in BAL are not specific for fat embolism but can also be detected with aspiration or other causes of lung injury [29, 30].

Fat embolism syndrome is a distinct and much less frequent entity, especially in children [31]. In this circumstance, a large bone marrow infarct (usually associated with excruciating pain) causes multiple fat embolisms which affect several organs, including the lung, and often determine rapid progression to acute respiratory distress syndrome and multiorgan failure [25, 32, 33]. In one study, at least 22% of cases of fat embolism syndrome were triggered by recent infection with parvovirus B19 [32].

Thromboembolic disease

In patients with SCD, the exact prevalence of pulmonary artery thromboembolism (PE) resulting from direct vaso-occlusion of the pulmonary vasculature is difficult to quantify because the clinical features frequently overlap with those of ACS. D-dimer is often elevated in ACS even in the absence of thromboembolism and, therefore, of limited utility. An autopsy study of 20 SCD adults found that 30% of those with fatal ACS had PE compared with none of those without ACS [34]. In a prospective study of 121 episodes of ACS in adults, PE was detected in 17% of cases on computed tomography pulmonary angiogram (CTPA) performed during the first 3 days of admission [35]. Pulmonary thromboembolism in the context of ACS has been only occasionally reported in children [36, 37]. ACS may not only be a consequence but also a risk factor for venous thromboembolism (VTE). In a retrospective paediatric cohort study, 40.1% of those with recurrent VTE had a previous episode of ACS and 65% of VTE recurrence occurred within 90 days of hospitalisation for ACS [38]. In these cases, it is likely that there was a bidirectional interplay between inflammation and coagulation [39].

A CTPA is recommended when pulmonary embolism is suspected (e.g. sudden onset unilateral pleuritic chest pain) [35, 40]. Thrombolytic treatment should be reserved for patients with confirmed thromboembolic disease or those in whom the index of suspicion is high until CTPA results are known.

Alveolar hypoventilation

Alveolar hypoventilation leading to CO2 retention and predisposing to atelectasis can occur in people with SCD, either due to splinting caused by severe bony pain from rib infarcts [41], opiate treatment or post-operatively following general anaesthetic. Atelectasis affects Vʹ/Qʹ mismatch in the lung, worsening hypoxia and favouring the cascade of events leading to ACS. Previous studies showed that up to 20% of patients with SCD undergoing abdominal surgery experience ACS episode post-operatively [17, 42]. Prevention of hypoventilation in patients with SCD is therefore of paramount important and chest physiotherapy has a central role for this purpose, as discussed later.

The role of nitric oxide, vascular cell adhesion molecule-1 and L-arginine

NO levels decrease during ACS episodes [43] due several factors, including reduced L-arginine availability, a substrate for nitric oxide synthase (NOS) [43], hypoxia-induced inhibition of NOS, increased NO scavenging by free Hb (released as a result of haemolysis) and by oxygen reactive species [44]. NO is a potent vasodilator, and it also plays an important role in inhibiting the upregulation of vascular cell adhesion molecule (VCAM-1). Children with SCD and ACS were found to have a marked increase in soluble VCAM-1 and associated reductions in NO metabolites [45]. These factors impair the physiological response to hypoxic pulmonary vasoconstriction and favour cell adhesion to pulmonary vascular endothelium, contributing to the vicious cycle of red blood cells sickling, vaso-occlusion and Vʹ/Qʹ mismatch.

Asthma

A diagnosis of asthma has been reported in up to 28% of patients with SCD [46, 47] and is associated with a higher risk of ACS [46, 48, 49]. The CSSCD cohort also showed that patients with SCD and a doctor diagnosis of asthma at school age, had earlier (median age of 2.4 versus 4.6 years) and more frequent episodes of ACS at preschool age [48], suggesting a bidirectional relationship between ACS, chronic airway inflammation and asthma [50].

Atopic asthma is more frequent in children with recurrent ACS episodes [51]. Positive skin-prick tests for aeroallergens [6], higher fractional exhaled NO levels, elevated total IgE levels and a history of wheezing have all been associated with increased incidence of ACS, even in the absence of a formal asthma diagnosis [46, 52, 53]. Asthma symptoms in the SCD population may have a heterogenous aetiology that include not only eosinophilic airway inflammation, but also low T-helper 2 chronic airway inflammation related to SCD respiratory pathophysiology and small airway compression from pulmonary vascular hyper flow in the context of chronic anaemia [54]. It is not clear why asthma may increase the risk of ACS and whether some of the different elements involved in aetiology of asthma symptoms in this population (e.g. chronic airway inflammation versus pulmonary blood overflow) are more specifically linked to ACS. A proposed mechanism is that an increased Vʹ/Qʹ mismatch due to asthma may cause tissue hypoxia, triggering the sickling of the red cells and the cascade of pathophysiological events that contribute to ACS [33].

Airway hyperresponsiveness (AHR) (demonstrated through a direct airway challenge) has been found in over 50% of children and adolescents with SCD, independent of a known history of asthma [55, 56]. However, a number of studies have failed to demonstrate an association between AHR and increased risk of ACS [57].

Obstructive sleep apnoea

In a large analysis of over 200 000 discharges of SCD patients in the USA, obstructive sleep apnoea (OSA) was associated with an increased risk of ACS (adjusted OR 1.34, 95% CI 1.08–1.67) [58]. However, due to the retrospective study design, a precise temporal relationship between OSA and ACS cannot be established from this data. Conversely, the large, multi-centre, prospective sickle cell anaemia study did not find an association between mean nocturnal oxygen saturation, oxygen desaturation index or obstructive apnoea hypopnoea index and future risk of ACS [59]. Thus, insufficient evidence exists to demonstrate a causal relationship between OSA and ACS.

Clinical presentation and diagnosis

ACS is characterised by acute onset of fever, chest pain, dyspnoea, cough, wheeze and hypoxia, accompanied by a new pulmonary infiltrate on chest radiography (CXR) [17, 40]. This broad definition encompasses different phenotypes, ranging from milder forms responding to antibiotics and supportive care (more common in children) to ACS rapidly progressing to acute respiratory distress syndrome and multi-organ failure [17].

Oxygen saturation measured by pulse oximetry (SpO2) may overestimate arterial oxygen saturation (SaO2) in black children and, in a tiny minority of cases, occult hypoxaemia may be present (SpO2 >92% and SaO2 <88%) [60]. In addition, patients with SCD have elevated levels dysfunctional haemoglobins, such as methaemoglobin and carboxyhaemoglobin, generated by the production of CO from haemolysis, which can further contribute to falsely high/reassuring SpO2 readings [61, 62]. Therefore, in black patients with ACS, when the degree of respiratory distress seems disproportionate to a relatively normal SpO2, the use of arterialised earlobe blood gas with co-oximetry should be considered [63]. This will better reflect the SaO2, although the gold standard remains arterial blood gas with co-oximetry, which is rarely performed in children outside paediatric intensive care units (PICUs) in the UK, as it is a painful procedure.

Fever, cough and hypoxia are the most common presenting features of ACS in children [40], which make it virtually impossible to distinguish from pneumonia. There are no signs or symptoms that are specific predictors of ACS: a clinical decision tool combining respiratory distress, hypoxia, cough or fever above 39°C coupled with Hb drop compared to baseline, C-reactive protein above 50 mg·L−1 and leukocytosis above 15 × 109 L–1 was found to have a sensitivity of 88% but a specificity of only 46% [64]. Moreover, clinical examination can be normal in up to 57% of children with ACS [3, 65]. In a 1-year prospective observational study of 96 febrile events in children with ACS assessed in the emergency department, a diagnosis of ACS was only suspected by the treating clinician before obtaining a CXR in 39% of cases [65]. Therefore, a CXR is warranted in every patient with SCD presenting to the emergency department with fever or other potential features of ACS.

Wheezing and chest tightness are also common in children with ACS. Especially in SCD patients with known asthma, just based on symptoms and clinical examination, an acute asthma attack could be easily misjudged as ACS and vice versa. Therefore, it is advisable to have a low threshold for obtaining CXR in the presence of acute asthma symptoms, particularly in patients who show a poor response to rescue bronchodilators.

Findings on CXR may differ between children and adults. Children more frequently have isolated upper lobe or middle lobe disease whilst lower lobe or multilobar pathology is more common in adults [3, 17], with the latter being an indicator of severity [17, 66]. Radiographic abnormalities can lag behind clinical manifestations [67]. Therefore, it is worth repeating a CXR when there is a clinical suspicion of ACS despite initial negative chest imaging. In this situation, alternative differentials of ACS should be considered, including acute asthma, pulmonary embolism, bony chest pain from rib infarction and pulmonary oedema from fluid overload or transfusion-related acute lung injury, with appropriate investigations arranged accordingly (e.g. CTPA for suspected PE). In a small minority of cases, chest CT may pick up lung consolidation that was missed by CXR [68].

The use of lung ultrasound (LUS) has also been evaluated to support the diagnosis of ACS. A meta-analysis of five studies, including 625 cases of possible ACS cases treated in the paediatric emergency department, showed that LUS had an overall sensitivity of 0.92 and 0.89 for a diagnosis of ACS compared with CXR, suggesting that LUS may be used as an initial screening tool for this purpose [69]. However, further evidence in this area is needed because, given that LUS is operator-dependent and influenced by the operator's skills, the studies included in the meta-analysis did not have a unifying definition of a new lung consolidation on chest ultrasound. Furthermore, two out of five were only published in the form of an abstract [69].

Management

Patients with ACS may deteriorate rapidly and therefore early treatment, close monitoring and multidisciplinary management is essential. Upon admission, all children with suspected ACS should have CXR, blood tests including full blood count, blood group and screen, basic biochemistry, microbiological investigations including blood culture (if febrile), bacterial respiratory culture from a sputum or a cough swab, and nasopharyngeal aspirate for respiratory viral PCR [40].

The mainstay of treatment is maintaining oxygenation and ventilation, hydration, analgesia, antibiotics, transfusion and prevention of atelectasis with incentive spirometry and chest physiotherapy (figure 1). Patients should be regularly monitored for signs of deterioration that may necessitate escalation to the PICU, such as worsening dyspnoea, hypoxaemia with high inspiratory oxygen fraction (FIO2) requirements or hypercapnia [40].

FIGURE 1 Clinical algorithm for acute chest syndrome (ACS) in children with sickle cell disease. BiLevel-PAP: bi-level positive airway pressure; HFNC: high-flow nasal cannula oxygen; NIV: noninvasive ventilation; NSAID: nonsteroidal anti-inflammatory drug; SpO2: oxygen saturation measured by pulse oximetry.

Antimicrobials

Randomised controlled trials (RCTs) are needed to assess the efficacy and safety of different antibiotic treatments in ACS. Until more evidence becomes available, antibiotics for ACS should include a macrolide for atypical cover [40], alongside coverage for Streptococcus pneumoniae according to local antibiotic resistance pattern (ceftriaxone is usually recommended) [63, 70, 71]. Influenza A should be treated aggressively with oseltamivir when suspected or proven [40, 72].

Blood transfusion

By increasing oxygen-carrying capacity, blood transfusions also play a significant role in the prevention and management of ACS. The evidence for the use of blood transfusion in ACS is limited [73] but clinical observation suggests its efficacy and it should be considered early in the course of disease [40]. A simple top-up transfusion may be indicated in patients with hypoxaemia, especially if SpO2 is <90% [40] or if there has been a drop in Hb levels compared to baseline. Exchange transfusion, which has the advantage of reducing the proportion of sickle erythrocytes without risking hyperviscosity, is indicated in those with hypoxaemia but Hb level >9.0 g·dL−1 (uncommon in ACS), or in severe cases, or in patients who are not improving despite an initial simple transfusion [73]. However, the decision to transfuse children with SCD should be discussed with the paediatric haematologist whenever possible as the potential benefits need to be weighed against the risks, including hyperviscosity, iron overload and alloimmunisation. These adverse effects are quite rare, however, with occasional one-off transfusions; they are more commonly seen in patients undergoing chronic transfusion therapy with 10 or more transfusions in a year [74, 75].

Prevention of hypoventilation and atelectasis

By encouraging deep inspiration and thus preventing atelectasis, incentive spirometry has been found to be highly effective in the primary prevention of ACS episodes in children admitted with acute chest or back pain, resulting in an 87% relative risk reduction of ACS [50, 76]. Thus, its use is recommended in all patients with vaso-occlusive pain crises [40] and it can be also useful for children with ACS. However, incentive spirometry requires cooperation and preschool children or patients with severe pain, shortness of breath or neurological impairment may be unable to perform it. In these cases, the use of positive expiratory pressure devices administered by a physiotherapist has been found to be noninferior to incentive spirometry in terms of patient satisfaction and length of hospital stay in a small, pilot study of 20 children [77]. The use of noninvasive ventilation (NIV) during sleep, when neither of the above two techniques can be performed, may also improve ventilation and oxygenation and has been found to be safe and well-tolerated in children with vaso-occlusive pain crises [78].

Oxygen therapy and respiratory support

Oxygen supplementation is indicated in patients with ACS if SpO2 <95% (oxygen saturation target 95–98%) or at least 3% below the patient's baseline [40]. Oxygen through nasal cannulae or simple face mask is usually sufficient for patients with milder ACS who can be managed in the general paediatric ward.

Continuous (24 h) NIV, in the authors’ view, is indicated for patients with more severe respiratory disease (e.g. moderate to severe work of breathing; FIO2 >50%; hypercapnia, drowsiness) and requires a high-dependency unit (HDU) or PICU environment. The preliminary evidence suggests that early NIV may prevent the need for intubation and ventilation in a proportion of children with severe ACS. In a 4-year retrospective analysis (2008–2012) of 65 paediatric patients with ACS admitted to the PICU of the Necker Hospital in Paris, 24-h bi-level positive airway pressure (BiLevel-PAP) through a nasal mask was started in all the patients at initial pressures of 10/4 cmH2O with uptitration or progressive weaning (median duration of treatment 7 days) according to clinical evolution [79]. Only three out 65 patients (4%) did not tolerate NIV and none of them required intubation and ventilation. On an extended analysis from 2008 to 2016, only four out 319 patients (1.2%) with ACS admitted to the PICU and started on 24-h NIV required intubation and ventilation [79]. This is remarkably less than previously reported in the NACCS study in the USA where, without an early NIV strategy, a total of 20 out of 410 children (4.8%) admitted to hospital with ACS required intubation and ventilation [17].

The effectiveness of heated and humidified high-flow nasal cannula (HFNC) oxygen delivery for ACS, as compared to low flow oxygen supplementation or to continuous positive airway pressure (CPAP)/BiLevel-PAP for more severe cases, has yet to be formally assessed at the best of the authors knowledge. HFNCs have the advantage of being easily accessible in most paediatric inpatient settings (at least in the UK), is generally well tolerated and has a good safety profile [80]. Although they have not been demonstrated specifically in children with SCD, there are several potential mechanisms through which an HFNC could benefit a patient with ACS and respiratory distress, including 1) improving mucociliary function and preventing drying of secretions, 2) helping to meet elevated peak inspiratory flow demands and alleviating inspiratory muscle effort, 3) increasing functional residual capacity and preventing atelectasis by delivering some positive end-expiratory pressure, and 4) washing out the CO2 from the upper airways [81]. The authors suggest considering starting HFNCs especially in children with ACS who have SpO2 in air <90% (for milder desaturation without increased work of breathing we would use low flow nasal cannula O2), or mild-to-moderate work of breathing, or multilobar involvement on CXR. There is, however, a need for future observational studies and international trials to formally investigate the role of HFNCs in ACS and to establish evidence-based parameters to guide escalation of respiratory support from simple oxygen supplementation to HFNCs to CPAP or BiLevel-PAP.

Until that evidence becomes available, the choice of the most adequate respiratory support in children with ACS needs to balance pros and cons on a case-by-case basis. More specifically, HFNCs have the great advantage of being more widely available and they are easier to tolerate than CPAP or BiLevel-PAP. However, nasal cannulae need to be of adequate size for the patient (outer diameter of the cannula occupying nor more than two-thirds that of the nares) [81] and an HFNC should not delay escalation to CPAP or BiLevel-PAP and admission to the HDU or PICU in sick patients (see above for more specific guidance). CPAP can improve oxygenation by reducing the expiratory collapse of small airways and preventing atelectasis, with subsequent positive impact on lung compliance and Vʹ/Qʹ matching. In addition, it may reduce the work of breathing by providing external support to the respiratory muscles, preventing exhaustion. However, CPAP is unlikely to be effective in patients with more severe respiratory distress desaturations and raised CO2 in contrast to BiLevel-PAP. Tolerance of CPAP or BiLevel-PAP can be an issue, especially in children. Moreover, the use of these supports should be very careful or even avoided in patients with ACS and impaired level of consciousness (e.g. patients needing high doses of opioids for pain control) due to the risk of aspiration, especially when a full-face mask is used.

NO and arginine supplementation

Given the depletion of NO and arginine during vaso-occlusive pain crises or ACS episodes, it would seem logical to treat patients with ACS with either of these substances. However, a prospective, multicentre, double-blind, RCT failed to find a difference in time to resolution of VOCs or frequency of ACS between inhaled NO and placebo [82]. In contrast, arginine supplementation was shown to reduce pain and time-to-resolution of VOCs in RCTs [83, 84]. Oral arginine therapy was associated with an 18% greater decrease in median tricuspid-regurgitant jet (TRJ) velocity (p<0.01) (elevated TRJ velocity is surrogate for pulmonary hypertension) in comparison to placebo in SCD paediatric patients presenting with pain or ACS [84]. Thus, arginine therapy may be an effective, low-cost adjunct to ACS treatment, particularly in low-income countries [85]. More research is required to ascertain whether interventions affecting the arginine–NO pathway or VCAM-1 are effective in the treatment of ACS.

Corticosteroids

The use of corticosteroids for children with moderate to severe ACS is controversial. Although an RCT has demonstrated a 40% reduced duration of hospital admission for children with ACS treated with intravenous dexamethasone [86], this was at the expense of an increased readmission rate within 72 h from discharge [86, 87]. A high readmission rate of 59% was also found in a retrospective study of children with ACS treated with either dexamethasone or prednisolone, including two patients readmitted with intracranial haemorrhage [88]. Evidence from transgenic sickle mice demonstrated that treatment with dexamethasone inhibited vaso-occlusion and leukocyte adhesion but resulted in a significant increase of inflammatory mediators, such as VCAM-1, and recurrence of VOC 3 days after discontinuation of treatment [89]. The findings of a recent systematic review, which included 86 participants from small RCTs, indicate that while corticosteroid use was linked to a significant 24-h decrease in hospital stay (95% CI −35–−14 h), the odds ratio for readmission was 3.28 (95% CI 1.46–7.36) [90], raising concerns that the risk of rebound attacks outperforms the positive effects of shortened hospital admission attributed to corticosteroid use in ACS.

However, this concern may not apply necessarily to all corticosteroids and all doses. In a retrospective study comparing people with SCD treated with low-dose prednisolone (1 mg·kg−1) with those who did not receive prednisolone, there were no increased readmission rates in the prednisolone group [91]. Furthermore, the rebound of symptoms seen following cessation of corticosteroids may reflect ongoing inflammation that was not adequately treated by a short course of corticosteroids, which may be ameliorated by a longer treatment course [92]. Larger RCTs are needed to assess whether specific corticosteroid regimens, if any, can be safely used in the treatment of ACS. At present, however, their routine use is not recommended but, in the authors view, it could be considered in patients with a comorbid diagnosis of asthma and overlap presentation ACS/asthma attack [40].

Prevention of ACS

RCTs in adults and children have shown that hydroxyurea reduces the risk of ACS in patients with SCD [93]. Chronic blood transfusion regimes have also been associated with a lower incidence of ACS in children at increased risk of stroke (i.e. abnormal transcranial doppler velocity) [74] or with one or more silent cerebral infarcts [94]. Furthermore, in the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) trial, patients who received pre-operative blood transfusion had a significantly lower incidence of ACS post-operatively [95]. A chronic blood transfusion regime and, more recently, stem cell transplantation, may be considered in children who continue to have recurrent ACS despite being on hydroxyurea [40]. These children should also be referred for a respiratory assessment in addition to haematological follow-up. Among the new disease-modifying therapies, in a phase III trial in children >5 years of age and adults, L-glutamine resulted in a significantly lower incidence of ACS in the study group (9%) versus the placebo group (23%; p=0.003) over 1-year follow-up [96]. To the best of the authors’ knowledge, there is no current evidence for the effectiveness of voxelotor and crizanlizumab in reducing the risk of ACS.

Impact of ACS on lung function

There is conflicting data on the impact of ACS episodes on lung function in children. A comparative cross-sectional study of children with SCD from Nigeria (n=154) and the UK (n=101) found that a history of ACS was associated with proportionally reduced forced expiratory volume in 1 s by −0.41 z-scores (95% CI −0.67–−0.17) and forced vital capacity by −0.35 z-scores (95% CI −0.60–−0.11) when adjusted for confounders [97]. A history of ACS was also associated with higher (more pathological) acinar ventilation heterogeneity values at multiple breath washout in a cohort of 35 young patients with SCD, potentially reflecting chronic intra-acinar lung impairment [98]. A longitudinal study including a cohort of 45 of children followed-up for a median period of 8 years showed that lung function declined with age. The rate of decline was greater in those with more frequent ACS episodes, who were also at higher risk of developing a restrictive lung function pattern over the time [10]. These findings, however, have not been confirmed in a prospective cohort of 104 paediatric patients with SCD with a median follow-up of 4 years [99]. In this study, an abnormal lung function pattern was not associated with previous ACS episodes or future risk of ACS [100]. Similarly, the occurrence of ACS episodes was not associated with greater lung function decline over time [99].

There are several possible explanations for the discrepancies between these studies, as described by Koumbourlis [101]. First, there are methodological differences between studies in defining both ACS and the cut-off values for abnormal lung function results. Furthermore, it may be that the effect of ACS on lung function relates to the severity of ACS episodes, which has rarely been considered, and not to their frequency. More prospective longitudinal studies with follow-up until adulthood are needed in order to define better the impact of ACS on long-term lung function, especially in the context of increasing use of hydroxyurea and other emerging disease-modifying drugs for SCD [102]. These treatments might not only mitigate or even revert the decline of lung function in patients with SCD [103], but they may also improve the long-term impact of ACS on their respiratory health [104].

Conclusions

ACS is a leading cause of morbidity and mortality in patients with SCD, with the greatest susceptibility in the preschool years. Preventative strategies, such as hydroxyurea started in infancy, have shown significant benefits in reducing the incidence of ACS. Given the risk of rapid deterioration, there should be a low threshold to suspect and treat ACS in any SCD patient presenting with fever and/or new respiratory symptoms or signs. Apart from the other supportive treatments, targeted respiratory care, including chest physiotherapy and the use of respiratory support when needed (ranging from HFNC to NIV), are an essential part of the care of these patients. Paediatric pulmonologists should be actively involved in the clinical management of children with moderate to severe ACS, alongside general paediatricians and paediatric haematologists, because the integration of skills from these subspecialities will likely result in improved the care and outcomes of these patients.

Points for clinical practice

The presenting features of ACS frequently overlap with lower respiratory tract infections and asthma. CXR should therefore be performed in all people with SCD presenting with one or more of the following signs or symptoms: temperature >38.5°C, chest pain, tachypnoea, wheezing, cough, increased work of breathing or hypoxaemia relative to baseline.

Incentive spirometry is highly effective in the primary prevention of ACS. Its use is recommended in all children presenting with vaso-occlusive pain crises and it can also be useful in ACS.

Noninvasive ventilation may prevent the need for intubation and ventilation and should be considered early in severe ACS.

Provenance: Submitted article, peer reviewed.

Author contributions: B. Ahmed and M. Arigliani wrote the manuscript. A. Gupta reviewed the manuscript and provided important intellectual content. All authors revised the manuscript and approved it for submission.

Conflict of interest: All authors have nothing to disclose.
==== Refs
References

1 Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013; 381 : 142–151. doi:10.1016/s0140-6736(12)61229-x 23103089
2 Payne AB, Mehal JM, Chapman C, et al. Trends in sickle cell disease-related mortality in the United States, 1979 to 2017. Ann Emerg Med 2020; 76 : S28–S36. doi:10.1016/j.annemergmed.2020.08.009 32928459
3 Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood 1997; 89 : 1787–1792. doi:10.1182/blood.V89.5.1787 9057664
4 Castro O, Brambilla D, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84 : 643–649. doi:10.1182/blood.V84.2.643.643 7517723
5 Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995; 86 : 776–783. doi:10.1182/blood.V86.2.776.bloodjournal862776 7606007
6 DeBaun MR, Rodeghier M, Cohen R, et al. Factors predicting future ACS episodes in children with sickle cell anemia. Am J Hematol 2014; 89 : E212–E217. doi:10.1002/ajh.23819 25088663
7 Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115 : 3447–3452. doi:10.1182/blood-2009-07-233700 20194891
8 Vance LD, Rodeghier M, Cohen RT, et al. Increased risk of severe vaso-occlusive episodes after initial acute chest syndrome in children with sickle cell anemia less than 4 years old: sleep and asthma cohort. Am J Hematol 2015; 90 : 371–375. doi:10.1002/ajh.23959 25619382
9 Knight-Madden JM, Forrester TS, Lewis NA, et al. The impact of recurrent acute chest syndrome on the lung function of young adults with sickle cell disease. Lung 2010; 188 : 499–504. doi:10.1007/s00408-010-9255-2 20644948
10 Lunt A, McGhee E, Sylvester K, et al. Longitudinal assessment of lung function in children with sickle cell disease. Pediatr Pulmonol 2016; 51 : 717–723. doi:10.1002/ppul.23367 26694220
11 Quinn CT, Shull EP, Ahmad N, et al. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 2007; 109 : 40–45. doi:10.1182/blood-2006-02-005082 16940426
12 Patterson GD, Mashegu H, Rutherford J, et al. Recurrent acute chest syndrome in pediatric sickle cell disease: clinical features and risk factors. J Pediatr Hematol Oncol 2018; 40 : 51–55. doi:10.1097/mph.0000000000001012 29200151
13 Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91 : 288–294. doi:10.1182/blood.V91.1.288 9414296
14 Assad Z, Michel M, Valtuille Z, et al. Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine in France. JAMA Netw Open 2022; 5 : e2225141. doi:10.1001/jamanetworkopen.2022.25141 35917121
15 Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood 2020; 136 : 2392–2400. doi:10.1182/blood.2020007645 32808012
16 Ruhl AP, Sadreameli SC, Allen JL, et al. identifying clinical and research priorities in sickle cell lung disease. an official American Thoracic Society workshop report. Ann Am Thorac Soc 2019; 16 : e17–e32. doi:10.1513/AnnalsATS.201906-433ST 31469310
17 Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342 : 1855–1865. doi:10.1056/nejm200006223422502 10861320
18 Strouse JJ, Reller ME, Bundy DG, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood 2010; 116 : 3431–3434. doi:10.1182/blood-2010-05-282194 20656929
19 Heilbronner C, Berteloot L, Tremolieres P, et al. Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit. Br J Haematol 2020; 190 : e21–e24. doi:10.1111/bjh.16802 32420608
20 Elia GM, Angel A, Regacini R, et al. Acute chest syndrome and COVID-19 in sickle cell disease pediatric patients. Hematol Transfus Cell Ther 2021; 43 : 104–108. doi:10.1016/j.htct.2020.11.005 33363267
21 Mucalo L, Brandow AM, Dasgupta M, et al. Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Adv 2021; 5 : 2717–2724. doi:10.1182/bloodadvances.2021004288 34196678
22 Ploton MC, Sommet J, Koehl B, et al. Respiratory pathogens and acute chest syndrome in children with sickle cell disease. Arch Dis Child 2020; 105 : 891–895. doi:10.1136/archdischild-2019-317315 32269038
23 Ochocinski D, Dalal M, Black LV, et al. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Review. Front Pediatr 2020; 8 : 38. doi:10.3389/fped.2020.00038 32154192
24 Dean D, Neumayr L, Kelly DM, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol 2003; 25 : 46–55. doi:10.1097/00043426-200301000-00010 12544773
25 Lechapt E, Habibi A, Bachir D, et al. Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2003; 168 : 1373–1377. doi:10.1164/rccm.200302-174OC 12969866
26 Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153 : 1691–1696. doi:10.1164/ajrccm.153.5.8630622 8630622
27 Maitre B, Habibi A, Roudot-Thoraval F, et al. Acute chest syndrome in adults with sickle cell disease. Chest 2000; 117 : 1386–1392. doi:10.1378/chest.117.5.1386 10807826
28 Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83 : 3107–3112. doi:10.1182/blood.V83.11.3107.3107 8193347
29 Lawlor CM, Choi SS. Lipid-laden macrophage index as a diagnostic tool for pediatric aspiration: a systematic review. OTO Open 2023; 7 : e33. doi:10.1002/oto2.33 36998564
30 Maddock SD, Cirulis MM, Callahan SJ, et al. Pulmonary lipid-laden macrophages and vaping. N Engl J Med 2019; 381 : 1488–1489. doi:10.1056/NEJMc1912038 31491073
31 Tsitsikas DA, Gallinella G, Patel S, et al. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non-SS genotypes and a possible association with human parvovirus B19 infection. Blood Rev 2014; 28 : 23–30. doi:10.1016/j.blre.2013.12.002 24468004
32 Tsitsikas DA, Vize J, Abukar J. Fat embolism syndrome in sickle cell disease. J Clin Med 2020; 9 : 3601. doi:10.3390/jcm9113601 33171683
33 Miller AC, Gladwin MT. Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med 2012; 185 : 1154–1165. doi:10.1164/rccm.201111-2082CI 22447965
34 Anea CB, Lyon M, Lee IA, et al. Pulmonary platelet thrombi and vascular pathology in acute chest syndrome in patients with sickle cell disease. Am J Hematol 2016; 91 : 173–178. doi:10.1002/ajh.24224 26492581
35 Mekontso Dessap A, Deux JF, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2011; 184 : 1022–1029. doi:10.1164/rccm.201105-0783OC 21836136
36 Villanueva H, Kuril S, Krajewski J, et al. Pulmonary thromboembolism in a child with sickle cell hemoglobin D disease in the setting of acute chest syndrome . Case Rep Pediatr 2013; 2013 : 875683. doi:10.1155/2013/875683 24159402
37 Staser JA, Alam T, Applegate K. Calcified pulmonary thromboembolism in a child with sickle cell disease: value of multidetector CT in patients with acute chest syndrome. Pediatr Radiol 2006; 36 : 561–563. doi:10.1007/s00247-006-0161-y 16708206
38 Brunson A, Keegan T, Mahajan A, et al. High incidence of venous thromboembolism recurrence in patients with sickle cell disease. Am J Hematol 2019; 94 : 862–870. doi:10.1002/ajh.25508 31074115
39 Nicola C, Erich VDP. Thromboinflammatory mechanisms in sickle cell disease – challenging the hemostatic balance. Haematologica 2020; 105 : 2380–2390. doi:10.3324/haematol.2019.239343 33054078
40 Howard J, Hart N, Roberts-Harewood M, et al. Guideline on the management of acute chest syndrome in sickle cell disease. Br J Haematol 2015; 169 : 492–505. doi:10.1111/bjh.13348 25824256
41 Rucknagel DL. The role of rib infarcts in the acute chest syndrome of sickle cell diseases. Pediatr Pathol Mol Med 2001; 20 : 137–154. doi:10.1080/15513810109168607 12673838
42 Wales PW, Carver E, Crawford MW, et al. Acute chest syndrome after abdominal surgery in children with sickle cell disease: is a laparoscopic approach better? J Pediatr Surg 2001; 36 : 718–721. doi:10.1053/jpsu.2001.22944 11329573
43 Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22 : 515–520. doi:10.1097/00043426-200011000-00009 11132219
44 Kyle Mack A, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol 2006; 38 : 1237–1243. doi:10.1016/j.biocel.2006.01.010 16517208
45 Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999; 94 : 1555–1560. doi:10.1182/blood.V94.5.1555 10477680
46 An P, Barron-Casella EA, Strunk RC, et al. Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity. J Allergy Clin Immunol 2011; 127 : 1440–1446. doi:10.1016/j.jaci.2010.12.1114 21388662
47 Strunk RC, Cohen RT, Cooper BP, et al. Wheezing symptoms and parental asthma are associated with a physician diagnosis of asthma in children with sickle cell anemia. J Pediatr 2014; 164 : 821–826.e1. doi:10.1016/j.jpeds.2013.11.034 24388323
48 Boyd JH, Macklin EA, Strunk RC, et al. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108 : 2923–2927. doi:10.1182/blood-2006-01-011072 16690969
49 Intzes S, Kalpatthi RV, Short R, et al. Pulmonary function abnormalities and asthma are prevalent in children with sickle cell disease and are associated with acute chest syndrome. Pediatr Hematol Oncol 2013; 30 : 726–732. doi:10.3109/08880018.2012.756961 23301782
50 DeBaun MR, Strunk RC. The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia. Lancet 2016; 387 : 2545–2553. doi:10.1016/s0140-6736(16)00145-8 27353685
51 Knight-Madden JM, Forrester TS, Lewis NA, et al. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 2005; 60 : 206–210. doi:10.1136/thx.2004.029165 15741436
52 Cohen RT, Rodeghier M, Kirkham FJ, et al. Exhaled nitric oxide: not associated with asthma, symptoms, or spirometry in children with sickle cell anemia. J Allergy Clin Immunol 2016; 138 : 1338–1343.e4. doi:10.1016/j.jaci.2016.06.043 27521278
53 Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52 : 565–571. doi:10.1093/cid/ciq237 21292659
54 Lunt A, Desai SR, Wells AU, et al. Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease. Thorax 2014; 69 : 746–751. doi:10.1136/thoraxjnl-2013-204809 24682519
55 Field JJ, Stocks J, Kirkham FJ, et al. Airway hyperresponsiveness in children with sickle cell anemia. Chest 2011; 139 : 563–568. doi:10.1378/chest.10-1243 20724735
56 De A, Manwani D, Rastogi D. Airway inflammation in sickle cell disease–a translational perspective. Pediatr Pulmonol 2018; 53 : 400–411. doi:10.1002/ppul.23932 29314737
57 Willen SM, Rodeghier M, Strunk RC, et al. Airway hyperresponsiveness does not predict morbidity in children with sickle cell anemia. Am J Respir Crit Care Med 2017; 195 : 1533–1534. doi:10.1164/rccm.201610-1970LE 28569575
58 Tsou PY, Cielo CM, Xanthopoulos MS, et al. The burden of obstructive sleep apnea in pediatric sickle cell disease: a kids’ inpatient database study. Sleep 2021; 44 : zsaa157. doi:10.1093/sleep/zsaa157 32835382
59 Willen SM, Rodeghier M, Rosen CL, et al. Sleep disordered breathing does not predict acute severe pain episodes in children with sickle cell anemia. Am J Hematol 2018; 93 : 478–485. doi:10.1002/ajh.25013 29266432
60 Ruppel H, Makeneni S, Faerber JA, et al. Evaluating the accuracy of pulse oximetry in children according to race. JAMA Pediatr 2023; 177 : 540–543. doi:10.1001/jamapediatrics.2023.0071 36939727
61 Caboot JB, Jawad AF, McDonough JM, et al. Non-invasive measurements of carboxyhemoglobin and methemoglobin in children with sickle cell disease. Pediatr Pulmonol 2012; 47 : 808–815. doi:10.1002/ppul.22504 22328189
62 Caboot JB, Allen JL. Hypoxemia in sickle cell disease: significance and management. Paediatr Respir Rev 2014; 15 : 17–23. doi:10.1016/j.prrv.2013.12.004 24461342
63 Arigliani M, Zheng S, Ruiz G, et al. Comparison of pulse oximetry and earlobe blood gas with CO-oximetry in children with sickle cell disease: a retrospective review. BMJ Paediatr Open 2020; 4 : e000690. doi:10.1136/bmjpo-2020-000690
64 Griffin R, Panayiotou A, Allen P, et al. What is the role of chest X-ray imaging in the acute management of children with sickle cell disease? Br J Haematol 2022; 196 : 402–413. doi:10.1111/bjh.17831 34528246
65 Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? Ann Emerg Med 1999; 34 : 64–69. doi:10.1016/s0196-0644(99)70273-8 10381996
66 Alkindi S, Al-Busaidi I, Al-Salami B, et al. Predictors of impending acute chest syndrome in patients with sickle cell anaemia. Sci Rep 2020; 10 : 2470. doi:10.1038/s41598-020-59258-y 32051480
67 Jain S, Bakshi N, Krishnamurti L. Acute chest syndrome in children with sickle cell disease. Pediatr Allergy Immunol Pulmonol 2017; 30 : 191–201. doi:10.1089/ped.2017.0814 29279787
68 Mekontso Dessap A, Deux JF, Habibi A, et al. Lung imaging during acute chest syndrome in sickle cell disease: computed tomography patterns and diagnostic accuracy of bedside chest radiograph. Thorax 2014; 69 : 144–151. doi:10.1136/thoraxjnl-2013-203775 23925645
69 Omar M, Jabir AR, Khan I, et al. Diagnostic test accuracy of lung ultrasound for acute chest syndrome in sickle cell disease: a systematic review and meta-analysis. Chest 2022; 163 : 1506–1518. doi:10.1016/j.chest.2022.11.042 36509124
70 Martí-Carvajal AJ, Conterno LO, Knight-Madden JM. Antibiotics for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2019; 9 : CD006110. doi:10.1002/14651858.CD006110.pub5 31531967
71 Payne AB, Link-Gelles R, Azonobi I, et al. Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009. Pediatr Infect Dis J 2013; 32 : 1308–1312. doi:10.1097/INF.0b013e3182a11808 23811745
72 van Tuijn CF, Nur E, van Beers EJ, et al. Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection. Am J Hematol 2010; 85 : 303–304. doi:10.1002/ajh.21638 20169545
73 Dolatkhah R, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2020; 1 : CD007843. doi:10.1002/14651858.CD007843.pub4 31942751
74 Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139 : 785–789. doi:10.1067/mpd.2001.119593 11743502
75 Kelly S, Belisário AR, Werneck Rodrigues DO, et al. Blood utilization and characteristics of patients treated with chronic transfusion therapy in a large cohort of Brazilian patients with sickle cell disease. Transfusion 2020; 60 : 1713–1722. doi:10.1111/trf.15818 32579245
76 Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333 : 699–703. doi:10.1056/nejm199509143331104 7637747
77 Hsu LL, Batts BK, Rau JL. Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry. Respir Care 2005; 50 : 624–627.15871756
78 Guenther CS, Pae VJ, Neri CM, et al. SNAP: Supportive noninvasive ventilation for acute chest syndrome prevention in children with sickle cell disease. Pediatr Blood Cancer 2021; 68 : e29136. doi:10.1002/pbc.29136 34101983
79 Heilbronner C, Merckx A, Brousse V, et al. Early noninvasive ventilation and nonroutine transfusion for acute chest syndrome in sickle cell disease in children: a descriptive study. Pediatr Crit Care Med 2018; 19 : e235–e241. doi:10.1097/pcc.0000000000001468 29356722
80 Mikalsen IB, Davis P, Øymar K. High flow nasal cannula in children: a literature review. Scand J Trauma Resusc Emerg Med 2016; 24 : 93. doi:10.1186/s13049-016-0278-4 27405336
81 Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care 2015; 3 : 15. doi:10.1186/s40560-015-0084-5 25866645
82 Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011; 305 : 893–902. doi:10.1001/jama.2011.235 21364138
83 Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013; 98 : 1375–1382. doi:10.3324/haematol.2013.086637 23645695
84 Onalo R, Cooper P, Cilliers A, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol 2021; 96 : 89–97. doi:10.1002/ajh.26028 33075179
85 Onalo R, Cilliers A, Cooper P, et al. Arginine therapy and cardiopulmonary hemodynamics in hospitalized children with sickle cell anemia: a prospective double-blinded randomized placebo-controlled trial. Am J Respir Crit Care Med 2022; 206 : 70–80. doi:10.1164/rccm.202108-1930OC 35426778
86 Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92 : 3082–3089. doi:10.1182/blood.V92.9.3082 9787142
87 Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330 : 733–737. doi:10.1056/nejm199403173301101 8107739
88 Strouse JJ, Takemoto CM, Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008; 50 : 1006–1012. doi:10.1002/pbc.21336 17849474
89 Belcher JD, Mahaseth H, Welch TE, et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2005; 288 : H2715–H2725. doi:10.1152/ajpheart.00986.2004 15665055
90 Lopinto J, Gendreau S, Berti E, et al. Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis. Haematologica 2022; 107 : 1914–1921. doi:10.3324/haematol.2021.280105 35021607
91 Kumar R, Qureshi S, Mohanty P, et al. A short course of prednisone in the management of acute chest syndrome of sickle cell disease. J Pediatr Hematol Oncol 2010; 32 : e91–e94. doi:10.1097/MPH.0b013e3181c29c52 20216237
92 Ogunlesi F, Heeney MM, Koumbourlis AC. Systemic corticosteroids in acute chest syndrome: friend or foe? Paediatr Respir Rev 2014; 15 : 24–27. doi:10.1016/j.prrv.2013.10.004 24268617
93 Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev 2017; 4 : CD002202. doi:10.1002/14651858.CD002202.pub2 28426137
94 DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med 2014; 371 : 699–710. doi:10.1056/NEJMoa1401731 25140956
95 Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013; 381 : 930–938. doi:10.1016/s0140-6736(12)61726-7 23352054
96 Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med 2018; 379 : 226–235. doi:10.1056/NEJMoa1715971 30021096
97 Arigliani M, Castriotta L, Zubair R, et al. Differences in lung function between children with sickle cell anaemia from West Africa and Europe. Thorax 2019; 74 : 1154–1160. doi:10.1136/thoraxjnl-2019-213717 31624220
98 Arigliani M, Kirkham FJ, Sahota S, et al. Lung clearance index may detect early peripheral lung disease in sickle cell anemia. Ann Am Thorac Soc 2022; 19 : 1507–1515. doi:10.1513/AnnalsATS.202102-168OC 35104199
99 Willen SM, Cohen R, Rodeghier M, et al. Age is a predictor of a small decrease in lung function in children with sickle cell anemia. Am J Hematol 2018; 93 : 408–415. doi:10.1002/ajh.25003 29226507
100 Cohen RT, Strunk RC, Rodeghier M, et al. Pattern of lung function is not associated with prior or future morbidity in children with sickle cell anemia. Ann Am Thorac Soc 2016; 13 : 1314–1323. doi:10.1513/AnnalsATS.201510-706OC 27300316
101 Koumbourlis AC. Acute chest syndrome, asthma, and lung function in sickle cell disease. which is the chicken, and which is the egg? Ann Am Thorac Soc 2016; 13 : 1212–1214. doi:10.1513/AnnalsATS.201606-452ED 27509149
102 Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol 2020; 11 : 435. doi:10.3389/fphys.2020.00435 32508672
103 Kotwal N, Pillai DK, Darbari DS, et al. Spirometric changes after initiation of hydroxyurea in children with sickle cell anemia. J Pediatr Hematol Oncol 2022; 44 : e923–e925. doi:10.1097/mph.0000000000002371 34966092
104 McLaren A, Klingel M, Behera S, et al. Effect of hydroxyurea therapy on pulmonary function in children with sickle cell anemia. Am J Respir Crit Care Med 2017; 195 : 689–691. doi:10.1164/rccm.201606-1119LE 28248149
